

AC710

Catalog No: tcsc3415



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1351522-04-7

Formula:

$C_{31}H_{42}N_6O_4$

Pathway:

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:

FLT3;PDGFR;c-Kit

Purity / Grade:

>98%

Solubility:

DMSO : 14 mg/mL (24.88 mM; Need ultrasonic and warming)

Observed Molecular Weight:


562.7

Product Description

AC710 is a potent **PDGFR** inhibitor with **K_d**s of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFR α and PDGFR β , respectively.

IC50 & Target: Kd: 0.6 nM (FLT3), 1.57 nM (CSF1R), 1 nM (KIT), 1.3 nM (PDGFR α), 1 nM (PDGFR β)^[1]

In Vivo: At 0.3 mg/kg of AC710, tumor growth is temporally inhibited, and growth resumes quickly thereafter. At 3 and 30 mg/kg of AC710, tumors regress completely, and the tumor volume stays suppressed for an extended period after dosing is halted. No body weight loss is observed in animals treated with AC710 at all doses, indicating that it is well tolerated in mice at efficacious doses. AC710 exhibits a significant impact on disease in a dose-dependent fashion in a mouse collagen-induced arthritis (CIA) model, at a dose as low as 3 mg/ kg for 15 days (day 0-14). At 10 and 30 mg/kg, AC710 demonstrates equivalent or slightly better efficacy in reducing the joint swelling and inflammation than dexamethasone administered at a safe dose. AC710 is well tolerated at the tested doses^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!